Depression is a leading cause of disability worldwide. Brain mechanisms underlying the clinical antidepressant efficacy of selective serotonin reuptake inhibitors (SSRI), currently the first-line treatment, remain poorly understood. Recent animal studies have implicated multiple serotonin receptor subtypes in SSRI response, opening new therapeutic perspectives.

CLINICAL QUESTION Are selective serotonin reuptake inhibitors (SSRIs) associated with better recovery after stroke? BOTTOM LINE SSRIs may be associated with improved recovery after stroke, even in persons without depression. However, much of the evidence is of poor quality. Large, high-quality trials are needed to evaluate the validity of the current evidence and improve precision of estimate...